Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma

Abstract

In this large study, tamoxifen did not improve the survival of patients with advanced HCC, but there is a suggestion that patients without major hepatic insufficiency seem to have some survival benefit. New trials involving this specific population are warranted.